Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

TB treatment news

Show

From To
New TB Treatment Options on Horizon

After nearly 50 years, the drug development pipeline for new tuberculosis (TB) treatments is finally opening up again, according to infectious disease specialists.

Published
20 March 2012
From
MedPage Today
TB Alliance Launches Combination Drug Trial, Establishes New Pathway to TB and MDR-TB Treatment

In an ambitious effort to stem the dangerous tide of tuberculosis (TB) and deadly drug-resistant TB around the world, TB Alliance today announced that it has launched a first-of-its-kind Phase II clinical trial to test a novel drug combination – in both patients who have TB, and those who have multidrug-resistant TB (MDR-TB).

Published
20 March 2012
From
TB Alliance
High dose of new HIV drug might improve outcomes for HIV/TB co-infected

A safety and tolerability study lookes at dolutegravir given twice daily with rifampin.

Published
08 March 2012
From
Science Speaks
World Health Organization issues new policy to step up TB/HIV efforts

Around 910,000 lives were saved between 2005 and 2010 as a result of closer working relationships between HIV and TB programmes, according to estimates released today by

Published
02 March 2012
By
Keith Alcorn
EMA Recommends First-Line Anti-TB Drugs for Children

The European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) agrees with the World Health Organization (WHO) dosing recommendations for ethambutol, isoniazid, pyrazinamide, and rifampicin as first-line antituberculosis medicines used in children, according to new EMA dosing guidelines released February 17.

Published
27 February 2012
From
Medscape (requires free registration)
HIV and TB in Practice for nurses

This is the first of a special monthly edition of HATiP for nurses and other health care workers involved in task-shifting in sub-Saharan Africa.

Published
03 February 2012
From
HIV & AIDS treatment in practice
Enrollment complete for REMOX TB - global phase III clinical trial of new TB drugs

The TB Alliance and its partners have completed patient enrollment in REMox TB, a global Phase III clinical trial, which may result in the registration of the first new drug approved for the treatment of drug-sensitive TB in nearly 50 years. REMox TB was designed to test whether a moxifloxacin-containing treatment regimen of just four months can cure drug-sensitive TB patients at rates that are non-inferior to those achieved with the standard six-month TB regimen.  In total, more than 1,900 patients were enrolled in REMox TB.

Published
02 February 2012
From
TB Alliance
New Shorter Treatment for Latent TB Not Recommended for HIV+ People on ART

Expert panels that put together the Department of Health and Human Services antiretroviral therapy (ART) guidelines have advised that the shorter and simpler combination regimen for latent tuberculosis (TB) recently recommended by the Centers for Disease Control and Prevention (CDC) is not suitable for people being treated for HIV.

Published
22 December 2011
From
HIVandHepatitis.com
New Six-Way Agreement Among Pharmas and NGOs will Speed Development of TB Drug Combinations

The Critical Path to TB Drug Regimens (CPTR) today announced an innovative agreement between AstraZeneca, Bayer, Sanofi, Tibotec, TB Alliance, and the World Health Organization to share information on tuberculosis (TB) compounds within their respective drug pipelines to quickly identify and work together to develop the most promising TB drug regimen, regardless of sponsor.

Published
10 November 2011
From
Critical Path to TB Drug Regimens
High Drug Prices Hamper Drug-Resistant TB Treatment

Access to treatment for drug-resistant tuberculosis (DR-TB) remains compromised, especially in developing countries, because too few pharmaceutical companies manufacture quality-assured drugs. Lack of competition has led to skyrocketing prices and this means that public health budgets are quickly spent.

Published
20 June 2011
From
Inter Press Service

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.